

### REMARKS

The Examiner states that restriction into one of the following groups of invention is required:

Group I, claims 1-9, 12, 14-17, 22-23 and 25, drawn to a method for mammalian cell activation requiring a naturally occurring embryo.

Group II, claims 1-9, 12-17, 22-23, 25, 50-51, 53-54 and 56-60, drawn to a method for mammalian cell activation requiring an embryo produced by in vitro fertilization and a method for in vitro fertilization.

Group III, claims 1-9, 11-17, 22-23, 25, 27-30, 35-36, 39-41, 46-47 and 49, drawn to a method for mammalian cell activation requiring a nuclear transfer embryo and methods for nuclear transfer cloning.

Group IV, claims 1-9, 12-17, 22-23 and 25, drawn to a method for mammalian cell activation requiring a uniparental embryo.

Group V, claims 18-21, 24, 26, 31-34, 37, 43-45, 48, 52 and 55, drawn to mammalian embryos, non-human offspring and activated mammalian cells.

Applicants elect the subject matter of group I with traverse for further prosecution in this application.


Applicants make this election without waiver of their right to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or by filing divisional or continuing applications claiming priority and benefit from this application, or a related application.

Application no. 10/747,772

1/10/06 Response to restriction requirement

Applicants request favorable consideration of the application and early allowance of the pending claims.

Respectfully submitted,

  
\_\_\_\_\_  
Stanley D. Liang  
Reg. No. 43,753  
Attorney for Applicants  
R. Minako Pazdera  
Reg. No. 46,984  
Agent for Applicants

FISH & NEAVE IP GROUP  
ROPES & GRAY LLP  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1105  
Tel.: (212) 596-9000  
Fax: (212) 596-9090